Back to News
Market Impact: 0.2
Benitec Biopharma FY26 Net Loss Widens; BB-301 Interim Data Due In October
Source: Nasdaq
Healthcare & BiotechCorporate EarningsCorporate Guidance & Outlook
Benitec Biopharma reported full-year fiscal 2026 financial results for the year ended June 30, 2026, and updated investors on upcoming clinical milestones for BB-301, its lead investigational candidate. The provided article text does not disclose financial figures, trial data, or specific milestone timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
BNTC0.35
More News
- Trip.com swings to Q2 loss after $763 million antitrust penalty
- Push for AI regulation mounts as talk of AI’s ‘existential’ risks go mainstream. But Trump resists calls for a slowdown
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Why Dave & Buster's Stock Tumbled Today
- Flotek Industries director Matthew Wilks adds $34.3m to holdings
- Trump calls AI fears a 'hoax', Treasury yields surge, Moynihan's warning and more in Morning Squawk